# Onchilles Pharma

Source: https://onco.cc/companies/onchilles-pharma/  
OnCo record `onchilles-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Onchilles Pharma makes N17350, an enzyme-based treatment injected into tumours that is designed to kill cancer cells while sparing immune cells, so the body's own defences can then attack the cancer. It is in an early trial in people with advanced solid tumours in the US and Australia.

## Summary

Onchilles Pharma, Inc., a private company in San Diego, California, co-founded by chief scientific officer Lev Becker, develops cytotoxic therapies built on what it calls the ELANE pathway, a cancer-selective killing mechanism linked to altered histone H1 biology in cancer cells. Its lead candidate N17350 (NEU-001) is a tumour-directed therapeutic elastase given by injection into the tumour; it is designed to cause immunogenic cancer cell death while preserving immune cells. The FDA cleared the IND on 2 February 2026, and the company announced the first patient dosed on 4 June 2026 in OP-NEU-101, a phase 1/2 open-label dose-finding and expansion study in advanced solid tumours at sites in the US and Australia; the registry lists triple-negative breast cancer, cutaneous squamous cell carcinoma, melanoma and head and neck cancers among the conditions. An intravenous counterpart, NEU-002, is in preclinical development. Its first registered cancer trial, NCT07339176, was posted on ClinicalTrials.gov in January 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Onchilles Pharma Inc
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.onchillespharma.com/

## Notes

- Founding year not stated on the company website.
- The company's newsroom lists a USD 7 million Series A as a headline, but the release text and its date were not read, so no funding row is recorded.
- ELANE (neutrophil elastase) is not a target record in the corpus, so no target id is set; the in-situ vaccination tag reflects the stated aim of an intratumoural treatment that triggers anti-tumour immunity.
- Preclinical breadth claims on the company website are not repeated here.
- Company website and releases read on 29 October 2026.

## Sources

- Official website: https://www.onchillespharma.com/
- IND clearance for N17350, February 2026: https://www.onchillespharma.com/post/onchilles-pharma-announces-ind-clearance-for-n17350
- First patient dosed with N17350, June 2026: https://www.onchillespharma.com/post/onchilles-pharma-doses-first-patient-in-phase-1-2-clinical-trial-of-n17350-for-advanced-solid-tumors
- ClinicalTrials.gov: phase 1/2 trial of intratumoural N17350 (NCT07339176): https://clinicaltrials.gov/study/NCT07339176

## Connected records

- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [In situ vaccination](https://onco.cc/technologies/in-situ-vaccination/)
- trials: [Intratumoral N17350 in Advanced Solid Tumors](https://onco.cc/trials/nct07339176/)

---
JSON: https://onco.cc/api/v1/entities/onchilles-pharma.json